Does mitotane treat metastases?

Mitotane was not originally a disease-treating drug, but as the drug was developed, it was gradually recognized as having important value in the treatment of adrenocortical tumors. Mitotane mainly inhibits tumor growth by interfering with the biosynthetic process of adrenocortical cells.

Whether mitotane can treat metastases varies from person to person. According to publicly released information, mitotane is widely used to treat metastatic adrenocortical carcinoma, a rare and aggressive malignancy. Through its unique mechanism, mitotane can slow down the growth of tumors and even achieve complete remission in some cases.

Specifically, mitotane can be effectively absorbed by the gastrointestinal tract after oral administration, and its blood drug concentration reaches its peak 3 to 4 hours after administration. The drug is widely distributed and stored primarily in fat tissue, which allows it to remain effective during long-term treatment. Although mitotane can bring certain therapeutic effects, patients also need to endure some adverse reactions, such as nausea, vomiting, central nervous system symptoms, etc.

In the treatment of metastases, the efficacy of mitotane is closely related to its plasma concentration. Several studies have shown that maintaining serum mitotane levels within a specific range is a strong predictor of efficacy. However, different patients may respond differently to mitotane, depending on a variety of factors, including tumor type, severity of disease, and the patient's medical condition.

Overall, mitotane plays an important role in the treatment of malignancies such as metastatic adrenocortical carcinoma. Although it is not a panacea and may cause some side effects, for many patients, mitotane provides an effective treatment option that can prolong survival and improve quality of life. Under the advice and guidance of a doctor, patients can consider whether to use mitotane for treatment according to their own conditions.